NCT00453427View on ClinicalTrials.gov

Alemtuzumab and CHOP Chemotherapy for Aggressive Histological Peripheral T-Cell Lymphomas

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

June 30, 2013

Study Completion Date

May 31, 2015

Conditions
Peripheral T-cell Lymphomas
Interventions
DRUG

Alemtuzumab (Campath-1H)

The investigational drug is alemtuzumab (Campath-1H). It is a recombinant humanized monoclonal antibody directed against the CD52 antigen on most (\> 95%) normal lymphocytes and T-cell and B-cell lymphomas. Alemtuzumab binds to the CD52 antigen on the cell surface, activating antibody-dependent cellular cytotoxicity, complement binding, apoptosis, cellular opsonization, and anti-tumour T-cell activity.

Trial Locations (5)

V6Z 1Y6

St. Paul's Hospital, Vancouver

L8V 5C2

Juravinski Cancer Centre, Hamilton

N6A 4G5

London Health Sciences Centre, London

M4N 3M5

Sunnybrook Health Sciences Centre, Odette Cancer Centre, Toronto

M5G 2M9

Princess Margaret Hospital, Toronto

All Listed Sponsors
collaborator

Sunnybrook Health Sciences Centre

OTHER

collaborator

Genzyme, a Sanofi Company

INDUSTRY

lead

Ontario Clinical Oncology Group (OCOG)

OTHER

NCT00453427 - Alemtuzumab and CHOP Chemotherapy for Aggressive Histological Peripheral T-Cell Lymphomas | Biotech Hunter | Biotech Hunter